FATE THERAPEUTICS INC Financing Cash Flow
FATE THERAPEUTICS INC (FATE) reported Financing Cash Flow of $1.74 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- FATE THERAPEUTICS INC net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $1.69M, a 46.01% decline year-over-year.
- FATE THERAPEUTICS INC net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $2.48M.
- FATE THERAPEUTICS INC net cash provided by (used in) financing activities for the quarter ending 2025-06-30 was $1.32M, a 4.00% increase year-over-year.
- FATE THERAPEUTICS INC net cash provided by (used in) financing activities for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- FATE THERAPEUTICS INC net cash provided by (used in) financing activities for fiscal 2025 was $5.49M, a 94.50% decline from fiscal 2024.
- FATE THERAPEUTICS INC net cash provided by (used in) financing activities for fiscal 2024 was $99.89M, a 117420.00% increase from fiscal 2023.
- FATE THERAPEUTICS INC net cash provided by (used in) financing activities for fiscal 2023 was $85.00K, a 99.08% decline from fiscal 2022.
- FATE THERAPEUTICS INC net cash provided by (used in) financing activities for fiscal 2022 was $9.21M, a 97.97% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.74M 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.17M derived: sum of 2 quarters · filed 2026-02-26 | $5.49M derived: sum of 3 quarters · filed 2026-08-13 | $5.49M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $3.80M derived: sum of 2 quarters · filed 2026-08-13 | $3.80M 10-Q · filed 2025-11-13 | $6.93M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.32M 10-Q · filed 2026-08-13 | $4.46M derived: sum of 3 quarters · filed 2026-08-13 | $4.46M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-13 | $3.13M derived: sum of 2 quarters · filed 2026-02-26 | $3.13M derived: sum of 3 quarters · filed 2026-02-26 | $4.40M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | $3.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.13M derived: sum of 2 quarters · filed 2026-02-26 | $4.40M derived: sum of 3 quarters · filed 2026-02-26 | $99.89M 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.27M derived: sum of 2 quarters · filed 2025-11-13 | $96.76M 10-Q · filed 2025-11-13 | $96.58M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $1.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $96.76M 10-Q · filed 2025-08-12 | $96.58M derived: sum of 3 quarters · filed 2025-08-12 | $96.58M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $95.49M 10-Q · filed 2025-05-13 | $95.31M derived: sum of 2 quarters · filed 2025-05-13 | $95.31M derived: sum of 3 quarters · filed 2025-05-13 | $95.37M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$180.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | -$180.00K derived: sum of 2 quarters · filed 2025-03-05 | -$122.00K derived: sum of 3 quarters · filed 2025-03-05 | $85.00K 10-K · filed 2025-03-05 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $58.00K derived: sum of 2 quarters · filed 2024-11-12 | $265.00K 10-Q · filed 2024-11-12 | $1.78M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $58.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $265.00K 10-Q · filed 2024-08-13 | $1.78M derived: sum of 3 quarters · filed 2024-08-13 | $3.27M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $207.00K 10-Q · filed 2024-05-09 | $1.72M derived: sum of 2 quarters · filed 2024-05-09 | $3.21M derived: sum of 3 quarters · filed 2024-05-09 | $6.62M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $3.00M derived: sum of 2 quarters · filed 2024-02-26 | $6.41M derived: sum of 3 quarters · filed 2024-02-26 | $9.21M 10-K · filed 2024-02-26 |
| 2022-09-30 | $1.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $4.89M derived: sum of 2 quarters · filed 2023-11-08 | $7.69M 10-Q · filed 2023-11-08 | $11.11M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $3.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $6.20M 10-Q · filed 2023-08-08 | $9.62M derived: sum of 3 quarters · filed 2023-08-08 | $17.56M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $2.80M 10-Q · filed 2023-05-03 | $6.21M derived: sum of 2 quarters · filed 2023-05-03 | $14.16M derived: sum of 3 quarters · filed 2023-05-03 | $17.88M derived: sum of 4 quarters · filed 2023-05-03 |
| 2021-12-31 | $3.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $11.36M derived: sum of 2 quarters · filed 2023-02-28 | $15.08M derived: sum of 3 quarters · filed 2023-02-28 | $453.13M 10-K · filed 2023-02-28 |
| 2021-09-30 | $7.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $11.66M derived: sum of 2 quarters · filed 2022-11-03 | $449.71M 10-Q · filed 2022-11-03 | $454.62M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $3.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $441.77M 10-Q · filed 2022-08-03 | $446.68M derived: sum of 3 quarters · filed 2023-02-28 | $447.61M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $438.05M 10-Q · filed 2022-05-04 | $442.96M derived: sum of 2 quarters · filed 2023-02-28 | $443.89M derived: sum of 3 quarters · filed 2023-02-28 | $719.44M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $4.91M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $5.84M derived: sum of 2 quarters · filed 2023-02-28 | $281.39M derived: sum of 3 quarters · filed 2023-02-28 | $282.84M 10-K · filed 2023-02-28 |
| 2020-09-30 | $930.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $276.48M derived: sum of 2 quarters · filed 2021-11-04 | $277.93M 10-Q · filed 2021-11-04 | $264.20M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $275.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $277.00M 10-Q · filed 2021-08-04 | $263.27M derived: sum of 3 quarters · filed 2022-02-28 | $424.98M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $1.45M 10-Q · filed 2021-05-05 | -$12.27M derived: sum of 2 quarters · filed 2022-02-28 | $149.43M derived: sum of 3 quarters · filed 2022-02-28 | $150.12M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$13.72M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $147.98M derived: sum of 2 quarters · filed 2022-02-28 | $148.67M derived: sum of 3 quarters · filed 2022-02-28 | $149.93M 10-K · filed 2022-02-28 |
| 2019-09-30 | $161.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $162.39M derived: sum of 2 quarters · filed 2020-11-05 | $163.65M 10-Q · filed 2020-11-05 | $165.56M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $688.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $1.95M 10-Q · filed 2020-08-05 | $3.85M derived: sum of 3 quarters · filed 2021-02-24 | $141.22M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $1.26M 10-Q · filed 2020-05-11 | $3.16M derived: sum of 2 quarters · filed 2021-02-24 | $140.53M derived: sum of 3 quarters · filed 2021-02-24 | $141.68M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $139.27M derived: sum of 2 quarters · filed 2021-02-24 | $140.43M derived: sum of 3 quarters · filed 2021-02-24 | $140.78M 10-K · filed 2021-02-24 |
| 2018-09-30 | $137.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $138.52M derived: sum of 2 quarters · filed 2019-11-05 | $138.88M 10-Q · filed 2019-11-05 | $182.12M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $1.51M 10-Q · filed 2019-08-06 | $44.75M derived: sum of 3 quarters · filed 2020-03-02 | $53.05M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $355.00K 10-Q · filed 2019-05-07 | $43.59M derived: sum of 2 quarters · filed 2020-03-02 | $51.89M derived: sum of 3 quarters · filed 2020-03-02 | |
| 2017-12-31 | $43.24M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $51.54M derived: sum of 2 quarters · filed 2020-03-02 | $47.36M 10-K · filed 2020-03-02 | |
| 2017-09-30 | $8.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $4.12M 10-Q · filed 2018-11-01 | ||
| 2017-06-30 | -$4.18M 10-Q · filed 2018-08-06 | |||
| 2016-12-31 | $57.74M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |